LUMIZYME (alglucosidase alfa) for Injection

First Page		Document Content
Date: 2010-05-26 09:39:24 Clinical medicine Neurochemistry Medicine Sodium channel blockers Alglucosidase alfa Calcium channel blockers Glycogen storage disease type II Ketamine Treprostinil Eptifibatide		LUMIZYME (alglucosidase alfa) for Injection Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 245,04 KB Share Document on Facebook

	How one patient with a rare disease coped with his genetic disorder DocID: 1r9mW - View Document
	LUMIZYME (alglucosidase alfa) for Injection DocID: 1qeuI - View Document
	United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP, DocID: 1oYEH - View Document
	Pompe disease (Glycogen storage disease type II) Glycogen storage disease type II is also known as acid maltase deficiency or generalized gl DocID: 1lJGD - View Document
	May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im DocID: 1aiEg - View Document